Holen Sie sich die Stockscreener-App
69.28
0.72%
-0.50
Handel nachbörslich:
70.70
1.42
+2.05%
Schlusskurs vom Vortag:
$69.78
Offen:
$70.93
24-Stunden-Volumen:
439.12K
Relative Volume:
0.73
Marktkapitalisierung:
$2.02B
Einnahmen:
$234.60M
Nettoeinkommen (Verlust:
$-13.23M
KGV:
-133.08
EPS:
-0.5206
Netto-Cashflow:
$19.61M
1W Leistung:
+4.80%
1M Leistung:
+20.11%
6M Leistung:
+92.44%
1J Leistung:
+234.20%
1-Tages-Spanne:
$68.39
$72.36
1-Wochen-Bereich:
$60.70
$72.36
52-Wochen-Spanne:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
69.28 | 2.03B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio (NASDAQ:ANAB) Reaches New 52-Week HighHere's Why - MarketBeat
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation - MSN
ANAB Maintained by Piper Sandler -- Price Target Lowered to $93 - GuruFocus
AnaptysBio CEO to appear at royalty company virtual conference - Stock Titan
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewswire
Biotech Momentum Builds Around AnaptysBio Shift - Kalkine Media
Piper Sandler Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute - Yahoo Finance
AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN
AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release - MSN
AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 14.7% in April - MarketBeat
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio rises after completing First Tracks spinoff - MSN
Director Susannah Gray receives 11,250 RSUs at AnaptysBio (ANAB) - Stock Titan
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AnaptysBio (ANAB) surges 14.8%: Is this an indication of further gains? - MSN
Rare skin disease drug study appears in NEJM Evidence before FDA date - Stock Titan
AnaptysBio (NASDAQ: ANAB) details spin-off, pay and board changes - Stock Titan
Fenwick Secures Chancery Court Victory for AnaptysBio in Licensing Dispute - fenwick.com
ANAB Rated Outperform by Leerink Partners -- Price Target Raised to $85 - GuruFocus
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighTime to Buy? - MarketBeat
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - Sahm
Why Is AnaptysBio Stock Soaring Monday?AnaptysBio (NASDAQ:ANAB) - Benzinga
AnaptysBio (NASDAQ:ANAB) Trading 11.2% HigherTime to Buy? - MarketBeat
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation (GSK:NYSE) - Seeking Alpha
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Yahoo Finance
GSK (NYSE: GSK) outlines TESARO–AnaptysBio dostarlimab litigation status and Jemperli growth - Stock Titan
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - MarketBeat
GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute - GuruFocus
GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong - AskTraders
Court favors AnaptysBio dismissing anticipatory breach claim - The Pharma Letter
GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim (GSK:NYSE) - Seeking Alpha
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation - GSK
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio - Proactive financial news
US court rules against GSK in dispute with AnaptysBio - Sharecast.com
GSK says unit Tesaro's claim for declaratory judgment against AnaptysBio unchanged - marketscreener.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics: Key Financial Impacts and Pro Forma Results - Minichart
Delaware court dismisses Tesaro breach claim against AnaptysBio By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling - GuruFocus
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):